Keytruda 50 mg/vial lyophilized powder for injection Images
Generic Name: pembrolizumab
This medication has been identified as Keytruda 50 mg/vial lyophilized powder for injection. It is supplied by Merck.
Keytruda is used in the treatment of Breast Cancer; Bladder Cancer; Cervical Cancer; Biliary Tract Tumor; Colorectal Cancer and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). There is positive evidence of human fetal risk during pregnancy. Keytruda 50 mg/vial lyophilized powder for injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Keytruda
- Generic Name
- pembrolizumab
- Strength
- 50 mg/vial lyophilized powder for injection
- Availability
- Prescription only
- Drug Class
- Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Merck
- National Drug Code (NDC)
- 00006-3029 (Discontinued)
More about Keytruda (pembrolizumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (239)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.